Physician profile
Shefali Vyas
NPI 1780676056
$2,538.30
in general payments reported to CMS, 2019-2025
10 companies · $2,279 in 2025
The $2,279 reported for 2025 was more than what 83% of Pediatric Nephrology providers received nationally (typical 2025 total: $131).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $14.91 · 2022: $23.44 · 2023: $188 · 2024: $33.54 · 2025: $2,279.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $2,200 · Food and Beverage: $268 · Education: $31.69.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $2,200.00 |
| Food and Beverage | $268.26 |
| Education | $31.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $2,200.00 | 2025 | Procysbi |
| Calliditas Therapeutics US INC. | $143.31 | 2023 | Tarpeyo |
| Azurity Pharmaceuticals, INC. | $48.87 | 2023-2025 | Triptodur, Katerzia, Katerzia |
| Recordati_rare_diseases_inc. | $28.87 | 2023 | Cystadrops |
| Apellis Pharmaceuticals, INC. | $23.45 | 2025 | Empaveli |
| Pfizer INC. | $23.44 | 2022 | |
| Aero US INC | $21.91 | 2025 | Aerogen Solo Nebulizer System, Aerogen Usb Controller System, Aerogen Solo; Aerogen Ultra |
| Merck Sharp & Dohme LLC | $18.09 | 2024 | Prevymis |
| Alexion Pharmaceuticals, INC. | $15.45 | 2024 | Ultomiris |
| Otsuka America Pharmaceutical, INC. | $14.91 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shefali Vyas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.